The unexpected early retirement of Pfizer’s chief executive and chairman, Jeffrey Kindler, drew various comments in the press with most commentators blaming his departure on the intense pressure that comes from running the world’s largest pharmaceutical company at a time when competition from generic pharmaceuticals is intensifying.
